Top Fully Remote Biotech Companies (41)
Don't see your company?
Create a company profile
Avadel (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. At Avadel, our core values foster an atmosphere of innovation and collaboration. In everything we do, we consider the patient experience, listening to their needs as we pursue the development and delivery of medicines that will transform the treatment landscape and have the greatest impact on people living with narcolepsy. Learn more about us at www.avadel.com and follow us on Twitter at @AvadelPharma.
At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine.
Please note that this company page is no longer updated. Meet us at https://www.linkedin.com/company/bio-rad-antibodies. As of May 17 2016, AbD Serotec, a Bio-Rad company changed its name to Bio-Rad. Following this re-branding, we created a new LinkedIn showcase page that features all the latest news, updates and useful resources from the antibody team at Bio-Rad. Please follow us on this new page (https://www.linkedin.com/company/bio-rad-antibodies) to keep in touch with us on LinkedIn.
Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0, a pipeline of targeted small-molecule drugs that overcome the limitations of existing treatments. Scorpion’s experienced leadership team is executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology. For more information, visit scorpiontx.com.
Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology. For more information, please visit www.matchpointtx.com.
Apogee Therapeutics, LLC is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders
Parachute is a new kind of plasma donation company that allows individuals to earn money while creating life-saving medicine. Plasma is used to create medicine that treats chronic illnesses, including immune disorders, liver disease, bleeding disorders, and cancer. Right now, there’s a severe plasma shortage, which is impacting patients’ access to these life-saving treatments
Altos Labs™ is a biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine. The company comprises a community of leading scientists, clinicians, and leaders from both academia and industry working together towards this common mission. Altos has operations in the San Francisco Bay Area and San Diego, and in Cambridge, UK, with significant collaborations in Japan. Note: Altos Labs will not ask you to download a messaging app for an interview or outlay your own money to get started as an employee. If this sounds like your interaction with people claiming to be with Altos, it is not legitimate and has nothing to do with Altos.
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines (excluding RNAi therapeutics) to treat human disease in ways that were not previously possible. We’re building a first-in-kind platform designed to sit at the intersection of RNA technology delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of vaccines, immunomodulation, protein replacement and regenerative medicine. Founded by experts in the fields of genetic medicine and RNA development and delivery, we have a dynamic operational structure designed to harness the ingenuity of a deep and diverse team of scientists, drug developers and business leaders.
iCarbonX is a technology company that is changing how people monitor and understand their health status and optimize their lives. We are building the platform and tools for digitizing, analyzing, and understanding life, and delivering intelligent products and applications—designed for every aspect and stage of life—to help everyone make smarter choices, every day. We’re inspired by every life on this planet, and by a commitment to apply intelligence not just to data, but to the ethical use of that data. Our mission is to bring people together to improve the human condition. We believe we must go beyond genetics to help people understand not just who they are, but how they are. We’re answering the “how” by combining biological and behavioral data with artificial intelligence in a network where people can learn from their own experience and from others like them, creating a global map of human health across cultures and continents that delivers new information and new choices, for life.
Protalix (NYSE, TASE: PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to gain FDA approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.
Trialwise is a woman-owned, boutique clinical research organization (CRO) specializing in early phase clinical studies and niche consulting. We intentionally partner with a limited number of biotech and pharma clients to offer a customized approach to managing projects efficiently without compromising quality, accuracy, or adherence to protocol and regulatory compliance. Since our inception, Trialwise has operated as a decentralized team working cross-functionally in an environment unencumbered by silos and bureaucracy. Our collaborative approach with our clients ensures we deliver the quality, personal attention, and cost efficiencies on which Trialwise has built its reputation. Trialwise president, Beth Brinsdon, founded the company in 1999 after two decades in the pharmaceutical industry. She observed that start-up and small-to-midsize biotech companies in the early stages of drug development require a high level of personalized service, a level that can be best provided by a small CRO. In 2015, she renamed the company to Trialwise and began scaling operations with a remote team to collaborate with select clients ranging from start-ups to established bio-pharma companies. The Trialwise approach is attentive, flexible, proactive, and committed to the highest quality industry standards in the following areas: - Protocol Development - Site Qualification - Risk Identification and Assessment - Study Start-up - Database Development and Management - Risk-based Management - Traditional Monitoring - Statistical Programming of CDISC Compliant Datasets - Statistical Analysis - Quality Assurance Oversight - Clinical Study Report Development - Document Processing and eCTD Compliant Granular ePub - Clinical Trial Registration and Results Disclosure - Staffing Support
ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.
We offer solutions that bridge artificial intelligence (AI) and machine learning (ML), physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, and consumer goods companies, and regulatory agencies worldwide.
The Public Health Company (PHC Global) is developing the first global biosecurity platform to provide enterprises a SaaS-enabled service for the management of bio-risks. PHC combines world-class expertise with cutting edge technology to be the global solution to enterprise risk management. PHC focuses on intersecting physical world threats across diverse use-cases to deliver actionable and predictive intelligence that enables dynamic risk management with unprecedented speed and scale
Aster Insights is a health informatics solutions company focused on accelerating the discovery, development, and delivery of personalized medicine. The company runs one the world’s largest observational research studies in cancer, which tracks patients throughout their lifetime, links longitudinal clinical data with molecular information, and enables a deeper understanding of a patient’s disease. Aster Insights has established one of the largest and most comprehensive linked clinical and genomic databases in the country, empowering innovative, collaborative cancer research and supporting the development of novel oncology drugs by its biopharmaceutical partners. Aster Insight’s data platform includes more than 400,000 patients across its alliance of leading cancer research centers, known as the Oncology Research Information Exchange Network (ORIEN). ORIEN members benefit through collaborative research and shared data; Aster Insight's biopharmaceutical partners benefit through access to the network and a dataset that supports clinical trial design, patient recruiting and new therapy development; and the ultimate beneficiaries are patients, as this process informs new drug treatment options. Indeed, Aster Insight’s data asset is unique in the market – and to date not widely known. Patient consent, as this brief explains, also gives it a significant competitive advantage to others emerging in this space. In December 2021, Aster Insights announced a formative collaboration with Microsoft to “to develop next generation data-driven solutions for oncology
Hi Fidelity Genetics is a computational biology company aiming to change the productivity of global agriculture
Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and the environment safer, healthier and more sustainable. From the food you eat to the medicines you rely on, Eurofins works with the biggest companies in the world to ensure the products they supply are safe, their ingredients are authentic and labelling is accurate. Eurofins is a global leader in food, environmental, pharmaceutical and cosmetic product testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In over just 30 years, Eurofins has grown from one laboratory in Nantes, France to over 61,000 staff across a network of over 1,000 independent companies in 59 countries, operating 940 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Eurofins is one of the fastest growing listed European companies. Since its IPO on the French stock exchange in 1997, Eurofins’ revenues have increased by 33% each year (in compound average) to reach €6.7 billion in 2021.
An AI-first therapeutics company. Nobias is currently running a phase 2 clinical trial for treating symptoms of anxiety, inattention, and autism in children with 22q11 deletion syndrome.
BioNews is a health media company focused on rare diseases and rare patient experiences. BioNews provides an insider’s view into disease and treatment news, condition management information, and community across more than 60+ diseases and brands. A fierce champion of the rare voice, BioNews brands are designed to reach, engage, and elevate even the smallest patient populations. We’re the only rare news and information property in the U.S. and are committed to the insider’s view into a rare disease or experience. People turn to our brands for timely treatment news, management, and community.
Work Your Passion. Live Your Purpose.
